Close

Magnetic Resonance Imaging of the Cardiovascular System - Cardiac MRI

Number: 0520



Policy

  1. Aetna considers magnetic resonance imaging (MRI) of the cardiovascular system medically necessary for the indications listed below, in accordance with guidelines developed by the American College of Cardiology Foundation, American College of Radiology (ACR) and the American Heart Association (AHA):

    1. Thoracic aortic disease

      For example: abnormal aortic contour or size on chest X-ray, differentiation of mediastinal mass versus vascular abnormality, to rule out aortic dissection, aneurysm, leaking thoracic aneurysm, exclude aortic source of peripheral embolization, Valsalva aneurysm, Marfan's syndrome and aorta annular actasia, after therapy of aortic dissection of aortic arch anomalies, coarctation, following aortic angioplasty, periaortic abscess or infection; or

    2. Pericardial disease

      For example: to assess pericardial thickness and detection of metastases, for diagnosing pericarditis and constriction, for diagnosing effusion and tamponade; or

    3. External or internal masses, pathology of lung and pleura

      For example: chest wall and mediastinal tumor invasion of the lung and pleura, lipoma, intracavity tumors, and differentiation of tumor from thrombus, assessment of vascular invasion, hilar assessment, and paracardial/cardiac invasion, pleural diseases; or

    4. Pathology involving surrounding structures

      For example: to evaluate intrinsic abnormalities of the pulmonary arteries, including central thrombi, aneurysms, stenoses, occlusions, dissection, and extra-vascular disease involving the pulmonary arteries; or

    5. Assessment of ventricular dysplasia; or

    6. Congenital heart disease

      For example: pulmonary atresia, severe obstruction to the right ventricular outflow tract, complex cyanotic heart disease, pulmonary venous anomalies, after surgery for correction of congenital heart disease; or

    7. Cardiac function, morphology, and structure when the following criterion is met:

      • After it has been determined that echocardiogram is inconclusive; or

    8. Atrial fibrillation, for assessing left atrial structure and function in persons with atrial fibrillation, and for identifying pulmonary vein anatomy prior to or after electrophysiology procedures.

    9. Diseases of the large veins

      For example: acquired and congenital abnormalities of the superior vena cavae, inferior vena cavae, and portal venous system (e.g., vena caval thrombus, differentiation of tumor thrombus and blood clot of the vena cava, superior vena caval syndrome, superior vena caval invasion or encasement by lung or mediastinal tumors, diagnosis of Budd-Chiari syndrome, and diagnosis of caval anomalies); or

    10. Valvular heart disease when the following criterion is met:

      • After it has been determined that echocardiogram and Doppler studies are inconclusive; or

    11. Demonstration of complications of infarction

      For example: formation of an aneurysm, mural thrombus formation, to demonstrate regional wall motion or wall thickening abnormalities of a damaged left ventricle.

    12. Peripheral arterial disease (PAD)

      To diagnose anatomical location and degree of stenosis of PAD and to select individuals with lower extremity PAD as candidates for endovascular intervention.

    13. Cardiomyopathy

      To evaluate cardiomyopathies (infiltrative [amyoid, sarcoid], hypertrophic cardiomyopathy, or due to cardiotoxic therapies).

    14. Myocarditis

      For further evaluation of suspected acute myocarditis

    15. Ventricular septal defect 

      To diagnose ventricular septal defect when echocardiography is not feasible or when echocardiographic findings are not diagnostic.

  2. Aetna considers MRI of the cardiovascular system experimental and investigational as a screening test for cardiovascular disease, for assessing acute coronary syndrome/acute non-specific chest pain, for detecting thrombi in the left atrial appendage in persons with atrial fibrillation, for acute rejection following heart transplantation, for predicting ventricular tachyarrhythmic events (e.g., sudden cardiac death, resuscitated cardiac arrest, the occurrence of ventricular arrhythmias, and appropriate implantable cardioverter defibrillator therapy) for evaluation of a dilated inferior vena cava, and for all other indications (except for the ones listed above).

  3. Aetna considers intravascular MRI experimental and investigational for detecting coronary vulnerable plaques.

  4. Aetna considers whole-heart coronary MRI experimental and investigational for the non-invasive evaluation of the coronary arteries.

Requests for cardiac MRI for indications that are not listed above are subject to medical review.

Any evidence of duplicative services, such as the use of computerized axial tomography (CT) scan, radionuclide studies, ultrasound, radioisotope scanning, sonograms and MRI, is subject to medical review for an evaluation of the medical necessity of the MRI.  There must be a compelling reason for multiple diagnostic procedures; in such situations, the MRI will only be considered medically necessary if the physician documents specific, necessary information to be gained from the additional test(s) that the initial test did not provide.  If a claim reveals that MRI was performed to detect a suspected medically necessary indication but instead demonstrated a non-medically necessary indication, the MRI will be considered medically necessary.

Background

Magnetic resonance imaging (MRI) is a non-invasive imaging procedure used primarily for studying intra-cranial and intra-spinal pathology, and for evaluating abnormalities of the musculoskeletal system, the heart, and pelvis.  It is also used to evaluate abdominal visceral problems.

Magnetic resonance imaging uses a pulsed radiofrequency wave in the presence of a high magnetic field to produce high quality images of the body in any plane.  Magnetic resonance imaging may be preferred to a compuetd tomography (CT) scan because of its established capability to depict soft tissue, often without the need for contrast material.

During a MRI examination, the patient is placed inside a very strong hollow magnet.  A fraction of the hydrogen atoms within the patient's body align themselves with the magnetic field.  The body area being examined is exposed to radio waves that are first absorbed and then emitted.  The emitted waves become the MRI signal.  The signal is analyzed by computer and processed into images of the body.  The images are usually in the form of slices through the body.  The slices can be taken in any plane.  Magnetic resonance imaging also has the ability to acquire 2-, 3- or 4-dimensional data.  Images with high signals appear white (e.g., fat) and those with low signals appear black (e.g., air in the lungs).

Magnetic resonance imaging is sometimes performed with the use of contrast agents for specific indications in order to achieve a desired image.  Contrast enhancement agents are approved by the Federal Drug Administration for use with MRI: Magnevist, (gadopentetate dimeglumine), ProHance, (gadoteritol), Omniscan, (gadodiomode), Ultravist, (iopromide), and Ferumoxsil (feroxide).

Magnetic resonance imaging has been shown to have several technical advantages in comparison to other standard diagnostic testing procedures such as CT scan and X-ray.  Magnetic resonance imaging is a non-invasive technique that uses no ionizing radiation and according to available literature, there are no known clinically significant side effects.  The literature indicates MRI can be used during the first trimester of pregnancy when it has been shown to offer an advantage over other modalities.  Magnetic resonance imaging does not always require contrast agents in order to achieve a high degree of resolution.  The literature indicates there is some increased risk of administering MRI contrast agents to patients with asthma or iodine allergy, but administration of these agents is still performed with caution.  Magnetic resonance imaging soft tissue contrast has been shown to be superior to that of other imaging modalities, and there are no image artifacts from bone.  The literature indicates MRI has greater inherent contrast between different types of normal body tissues and between pathological tissues and normal tissues.  Magnetic resonance imaging clarity is equal in any view: axial, sagittal, coronal, or oblique.  Magnetic resonance imaging also has the ability to acquire 2-dimensional, 3-dimensional and 4-dimensional data.

Magnetic resonance imaging has been shown to have several disadvantages.  It requires more patient cooperation than other tests.  Imaging time is longer than CT or X-ray.  Exposure time of MRI is between 100 and 1,000 times as long as the time required for a CT slice.  Installation and operation of MRI equipment is costly.  It has limitations in the acute trauma setting due to its incompatibility with various medical and life support devices.  Transient biological effects have been noted, such as cardiac T-wave changes.  Overheating may result from the alternating magnetic transmissions of the radiofrequency coils.  The literature indicates that care should be exercised when using MRI with infants, elderly patients, and hyperpyrexic individuals.  There is a forceful attraction of ferromagnetic objects to the magnet.  Most aneurysm clips, intra-cranial or intra-ocular metal, shrapnel, cardiac pacemakers or pacemaker wires and cochlear implants are absolute contraindications for MRI.  Magnetic resonance imaging has somewhat less spatial resolution than CT scan.  According to the literature, incidental anatomic discrepancies, such as non-specific white matter abnormalities, may be misinterpreted as causing the patient's symptoms. 

Magnetic resonance imaging in the field of cardiology is evolving at a dynamic pace.  However, because of the lack of availability of state of the art MRI technology and expertise, echocardiography, in particular trans-esophageal echocardiogram (TEE), remains the generally accepted modality for the evaluation of cardiac anatomy and function most of the time by most practitioners.  According to the literature, 50 to 60 % of the population can not be adequately imaged with echocardiogram.  For these patients, MRI has been shown to be particularly important.  Magnetic resonance imaging has the following important attributes that make it effective for the evaluation of the cardiovascular system:

  • Fast gradient echo techniques can be used to assess global and regional ventricular contractile function;
  • It can produce high resolution images of the cardiac chambers and large vessels without the need of contrast agents;
  • It does not have difficulties in evaluating right ventricular function;
  • It does not have the weakness of geometric assumptions as does angiography and echocardiography in the assessment of ventricular volumes;
  • It has high tissue contrast;
  • It is a 3-dimensional imaging technique;
  • It produces images of cardiovascular structures without the interference from adjacent bone or air; and
  • Velocity encoded techniques permit measurement of blood flow.

Since MRI can usually not be brought to the bedside like the TEE, it may not be the first test used in an emergency situation, but may be used to better define the diagnosis.  Under established guidelines, MRI is used as the diagnostic test for the following indications: diseases of the aorta, diseases of the pericardium, external and internal masses, pathology involving surrounding structures, congenital heart disease, and ventricular dysplasia.  Magnetic resonance imaging is increasingly being used in the assessment of cardiac function, morphology and structure.  When echocardiography does not provide enough information, in these circumstances, the literature suggests MRI may be warranted.

García-García et al (2008) noted that thin-capped fibroatheroma is the morphology that most resembles plaque rupture.  Detection of these vulnerable plaques is essential for studying their natural history and assessing potential therapies and, thus, may have an important impact on the prevention of myocardial infarction and death.  At the present time, conventional grayscale intra-vascular ultrasound, virtual histology and palpography data are being collected with the same catheter during the same pullback.  A combination of this catheter with either thermography capability or additional imaging, such as optical coherence tomography or spectroscopy, would be an exciting development.  Intra-vascular MRI also holds much promise.  To date, none of the techniques described above has been sufficiently validated and, most importantly, their predictive value for adverse cardiac events remains elusive.  Very rigorous and well-designed studies are compelling for defining the role of each diagnostic modality.  Until vulnerable plaques can be detected accurately, no specific treatment is warranted.

Hauser and Manning (2008) stated that the non-invasive detection of coronary artery disease has been a major goal of newer cardiac imaging technologies.  In the past 10 years, coronary MRI has undergone significant advances, resulting in excellent sensitivity for detecting coronary artery disease.  The authors noted that whole-heart coronary MRI, a technique that is similar to coronary CT angiography, has emerged as a promising approach for the non-invasive evaluation of the coronary arteries.  This is in agreement with the observation of Schaar et al (2007) who noted that the role of non-invasive imaging in vulnerable plaque detection is currently under investigation.  Several invasive and non-invasive techniques (e.g., MRI and multi-slice spiral CT) are currently under development to evaluate the vulnerable plaque.  However, none has proven its value in an extensive in-vivo validation and all have a lack of prospective data.

In a review on the use of cardiac MRI in the diagnosis of acute coronary syndrome (ACS), Breuckmann et al (2008) noted that in contrast to chronic myocardial infarction, data concerning the value of cardiac MRI in patients with acute onset of chest pain are still rare.  Even in the presence of characteristic clinical parameters, cardiac MRI might provide independent evidence especially in the absence of typical ECG alterations and prior to biomarker elevation.  Besides the ability to demonstrate wall motion abnormalities, cardiac MRI gains additional potential as to the detection of myocardial edema, microvascular obstruction (no-reflow) and myocardial necrosis.  However, cardiac MRI is expensive and time-consuming, and thus may not be cost-effective.  Currently, a lack of sufficient diagnostic and prognostic data would make cardiac MRI  unsuitable for routine stratification of chest pain patients in an emergency department.

Lockie and colleagues (2009) stated that the role of cardiac MRI in the assessment of ACS is less well-established.  Future larger studies will determine more fully the role of cardiac MRI in the setting of ACS.  The American College of Radiology's Expert Panel on Cardiac Imaging (Hoffman et al, 2011) rendered a "2' rating for MRI of heart with or without stress without contrast; and a "3" rating for MRI of heart with or without stress without and with contrast for evaluation of patients with acute non-specific chest pain (rating Scale: 1,2,3 means "usually not appropriate"; 4,5,6  means "may be appropriate"; and 7,8,9 means "usually appropriate").

A report of the American College of Cardiology Foundation task force on cardiovascular magnetic resonance (Hundley et al, 2010) stated that cardiovascular MRI (performed with gandolinium enhancement) is recommended to diagnose anatomical location and degree of stenosis of peripheral arterial disease (PAD) and to select patients with lower extremity PAD as candidates for endovascular intervention.

The ACC report stated that cardiac MRI may be used for assessing left atrial structure and function in patients with atrial fibrillation, and may be useful for identifying pulmonary vein anatomy prior to or after electrophysiology procedures without need for patient exposure to ionizing radiation.  The report also noted that standardization of protocols and more studies are needed to ascertain whether cardioavascular MRI provides a reliable method for detecting thrombi in the left atrial appendage in patients with atrial fibrillation.

An UpToDate review on “Ventricular septal defect in adults” (Ammash and Connolly, 2013) states that “Cardiovascular magnetic resonance (CMR) imaging and computed tomography (CT) can provide accurate, reliable and reproducible assessment of cardiac structure and function in congenital heart disease when performed by an expert.  These techniques offer certain advantages over echocardiography since they allow unrestricted evaluation of cardiac chambers and great arteries not compromised by air, bone, or surgical scar.  Summation of disks on multiple tomographic slices during ventricular diastole and systole permits direct and accurate measurement of left ventricular volume and function.  Such data is helpful in timing intervention or repair in adults with VSDs.  However, these techniques have not been widely adopted in the evaluation of VSD primarily because echocardiography is widely available and provides sufficient information in most cases and CMR and cardiac CT have more limited availability”. 

MedlinePlus, a service of the U.S. National Library of Medicine, notes that cardiac MRI is one of the tests that are used for evaluation of VSD. The Adult Congenital Heart Association (ACHA) states that tests to confirm the presence and effect of a VSD may include cardiac MRI.

In an eMedicine review on “Ventricular septal defects”, Ramaswamy (2013) states that “ MRI is a useful adjunct tool, but it is infrequently required for the diagnosis of VSDs.  As a rule, it is employed only when ultrasonography is not feasible or when ultrasonographic findings are not diagnostic.  However, because MRI data about systemic and pulmonary flows are been well-validated and well-correlated with catheterization data, one of the indications for the use of MRI is evaluation of a VSD that is judged to be borderline during echocardiography in terms of the level of the left-to-right shunt.  For such defects, an MRI-derived Qp:Qs may assist the clinician in making the decision whether to proceed with surgical treatment.

Sarcoidosis and amyloidosis are both multi-system disorders, which may involve the heart; however, isolated cardiac disease is rare.  Diagnosis of cardiac sarcoidosis and amyloidosis is crucial because the patient prognosis is dependent on cardiac involvement and early treatment.  Bauner and Wintersperger (2013) stated that echocardiography is the first line imaging modality in the diagnostic work-up of both diseases, possibly giving hints towards the correct diagnosis.  Besides myocardial biopsy and radionuclide studies cardiac MRI is routinely performed in patients suspect of having infiltrative cardiomyopathy.  The T1 mapping procedure is currently being evaluated as a new technique for detection and quantification of global myocardial enhancement, as seen in cardiac amyloidosis.  Sensitivities and specificities for detection of cardiac sarcoidosis and amyloidosis can be significantly improved by MRI, especially with late gadolinium enhancement (LGE) imaging.  In cardiac sarcoidosis the use of LGE is outcome-related while in amyloidosis analysis of T1-mapping may be of prognostic value.  The authors recommended that if cardiac involvement in sarcoidosis or amyloidosis is suspected cardiac MRI including LGE should be performed for establishing the diagnosis.

An UpToDate review on “Cardiac sarcoidosis” (McKenna, 2013) states that “In patients with abnormalities after the initial evaluation, we suggest noninvasive imaging, preferably with cardiovascular magnetic resonance imaging (CMR) and FDG PET to enhance disease detection and monitoring of treatment response.  If neither CMR nor PET is available, we suggest a gallium, thallium, or technetium scan”.

Maron (2012) stated that hypertrophic cardiomyopathy (HCM) is characterized by substantial genetic and phenotypic heterogeneity, leading to considerable diversity in clinical course including the most common cause of sudden cardiac death (SCD) in young people and a determinant of heart failure symptoms in patients of any age.  Traditionally, 2-dimensional echocardiography has been the most reliable method for establishing a clinical diagnosis of HCM.  However, cardiovascular magnetic resonance (CMR), with its high spatial resolution and tomographic imaging capability, has emerged as a technique particularly well-suited to characterize the diverse phenotypic expression of this complex disease.  For example, CMR is often superior to echocardiography for HCM diagnosis, by identifying areas of segmental hypertrophy (i.e., anterolateral wall or apex) not reliably visualized by echocardiography (or under-estimated in terms of extent).  High-risk HCM patient subgroups identified with CMR include those with thin-walled scarred left ventricular (LV) apical aneurysms (which prior to CMR imaging in HCM remained largely undetected), end-stage systolic dysfunction, and massive LV hypertrophy.  Cardiovascular magnetic resonance observations also suggested that the cardiomyopathic process in HCM is more diffuse than previously regarded, extending beyond the LV myocardium to include thickening of the right ventricular wall as well as substantial morphologic diversity with regard to papillary muscles and mitral valve.  These findings have implications for management strategies in patients undergoing invasive septal reduction therapy.  Among HCM family members, CMR has identified unique phenotypic markers of affected genetic status in the absence of LV hypertrophy including: myocardial crypts, elongated mitral valve leaflets and late gadolinium enhancement (LGE).  The unique capability of contrast-enhanced LGE-CMR to identify myocardial fibrosis has raised the expectation that this may represent a novel marker, which may enhance risk-stratification.  At this time, LGE appears to be an important determinant of adverse LV re-modeling associated with systolic dysfunction.  However, the predictive significance of LGE for SCD is incompletely resolved and ultimately future large prospective studies may provide greater insights into this issue.

Green et al (2012) performed a systematic review and meta-analysis of the predictive value of LGE-CMR for future cardiovascular events and death in patients with HCM.  These investigators searched multiple databases including PubMed for studies of LGE in HCM that reported selected clinical outcomes (cardiovascular mortality, SCD, aborted SCD, and heart failure death).  They performed a systematic review of the literature and meta-analysis to determine pooled odds ratios for these clinical events.  A total of 4 studies evaluated 1,063 patients over an average follow-up of 3.1 years.  The pooled prevalence of LGE was 60 %.  The pooled odds ratios (OR) demonstrated that LGE-CMR correlated with cardiac death (pooled OR: 2.92, 95 % confidence interval [CI]: 1.01 to 8.42; p = 0.047), heart failure death (pooled OR: 5.68, 95 % CI: 1.04 to 31.07; p = 0.045), and all-cause mortality (pooled OR: 4.46, 95 % CI: 1.53 to 13.01; p = 0.006), and showed a trend toward significance for predicting sudden death/aborted sudden death (pooled OR: 2.39, 95 % CI: 0.87 to 6.58; p = 0.091).  The authors concluded that LGE- CMR has prognostic value in predicting adverse cardiovascular events among HCM patients.  There are significant relationships between LGE and cardiovascular mortality, heart failure death, and all-cause mortality in HCM.  Additionally, LGE and SCD/aborted SCD displayed a trend toward significance.  They stated that assessment of LGE-CMR has the potential to provide important information to improve risk-stratification in HCM in clinical practice.

Gulati et al (2013) examined if myocardial fibrosis (detected by LGE-CMR imaging) is an independent and incremental predictor of mortality and SCD in dilated cardiomyopathy.  Prospective, longitudinal study of 472 patients with dilated cardiomyopathy referred to a United Kingdom center for CMR imaging between November 2000 and December 2008 after presence and extent of mid-wall replacement fibrosis were determined.  Patients were followed-up through December 2011.  Primary end point was all-cause mortality.  Secondary end points included cardiovascular mortality or cardiac transplantation; an arrhythmic composite of SCD or aborted SCD (appropriate ICD shock, non-fatal ventricular fibrillation, or sustained ventricular tachycardia); and a composite of heart failure (HF) death, HF hospitalization, or cardiac transplantation.  Among the 142 patients with mid-wall fibrosis, there were 38 deaths (26.8 %) versus 35 deaths (10.6 %) among the 330 patients without fibrosis (hazard ratio [HR], 2.96 [95 % CI: 1.87 to 4.69]; absolute risk difference, 16.2 % [95 % CI: 8.2 % to 24.2 %]; p < 0.001) during a median follow-up of 5.3 years (2,557 patient-years of follow-up).  The arrhythmic composite was reached by 42 patients with fibrosis (29.6 %) and 23 patients without fibrosis (7.0 %) (HR, 5.24 [95 % CI: 3.15 to 8.72]; absolute risk difference, 22.6 % [95 % CI: 14.6 % to 30.6 %]; p < 0.001).  After adjustment for left ventricular ejection fraction (LVEF) and other conventional prognostic factors, both the presence of fibrosis (HR, 2.43 [95 % CI: 1.50 to 3.92]; p < 0.001) and the extent (HR, 1.11 [95 % CI: 1.06 to 1.16]; p < .001) were independently and incrementally associated with all-cause mortality.  Fibrosis was also independently associated with cardiovascular mortality or cardiac transplantation (by fibrosis presence: HR, 3.22 [95 % CI: 1.95 to 5.31], p < 0.001; and by fibrosis extent: HR, 1.15 [95 % CI: 1.10 to 1.20], p < 0.001), SCD or aborted SCD (by fibrosis presence: HR, 4.61 [95 % CI: 2.75 to 7.74], p < 0.001; and by fibrosis extent: HR, 1.10 [95 % CI: 1.05 to 1.16], p < 0.001), and the HF composite (by fibrosis presence: HR, 1.62 [95 % CI: 1.00 to 2.61], p = 0.049; and by fibrosis extent: HR, 1.08 [95 % CI: 1.04 to 1.13], p < 0.001).  Addition of fibrosis to LVEF significantly improved risk re-classification for all-cause mortality and the SCD composite (net re-classification improvement: 0.26 [95 % CI: 0.11 to 0.41]; p = 0.001 and 0.29 [95 % CI: 0.11 to 0.48]; p = 0.002, respectively).  The authors concluded that assessment of mid-wall fibrosis with LGE-CMR imaging provided independent prognostic information beyond LVEF in patients with non-ischemic dilated cardiomyopathy.  They stated that the role of LGE-CMR in the risk-stratification of dilated cardiomyopathy requires further investigation.

Scott et al (2013) noted that approaches to the risk-stratification for SCD remain unsatisfactory.  Although LGE-CMR for SCD risk-stratification has been evaluated in several studies, small sample size has limited their clinical validity.  These investigators performed a meta-analysis to better-gauge the predictive accuracy of LGE-CMR for SCD risk-stratification.  Electronic databases and published bibliographies were systematically searched to identify studies evaluating the association between the extent of LV scar on LGE-CMR and ventricular arrhythmic events [SCD, resuscitated cardiac arrest, the occurrence of ventricular arrhythmias, or appropriate implantable cardioverter defibrillator (ICD) therapy].  Only studies enrolling patients with CAD or non-ischemic cardiomyopathy were included.  Summary estimates of the relative risk (RR) and likelihood ratios (LRs) were calculated using random effects models.  A total of 11 studies comprising 1,105 patients were identified.  During a mean/median follow-up of 8.5 to 41 months 207 patients had ventricular arrhythmic events.  Ventricular arrhythmic events were more common in patients with a greater extent of LV scar: RR 4.33 [95 % CI: 2.98 to 6.29], positive LR 1.98 (95 % CI: 1.66 to 2.37), and negative LR 0.33 (95 % CI: 0.24 to 0.46).  The authors concluded that the extent of LGE on CMR is strongly associated with the occurrence of ventricular arrhythmias in patients with reduced left ventricular ejection fraction and may be a valuable risk-stratification tool for identifying patients who will benefit from ICD therapy.  However, they stated that uncertainties regarding clinical application persist and need to be addressed prior to introduction into broad clinical practice.

den Hartog et al (2013) provided an overview of the literature that assessed the agreement between MRI and histology for specific carotid plaque characteristics associated with vulnerability in terms of sensitivity and specificity.  A systematic search strategy was conducted in MEDLINE and EMBASE databases resulting in 1,084 articles; these investigators included 17 papers.  Due to variation in presentation, especially in MRI and histology methods, a pooled analysis could not be performed.  Two studies were performed on a 3.0-T MRI scanner; all other studies were performed on a 1.5-T scanner.  Most performed sequences were two-dimensional (2-D) and 3-D T1-weighted and all histology protocols varied slightly.  These findings indicated that calcification, fibrous cap, intra-plaque hemorrhage (IPH) and lipid-rich necrotic cores can be identified with moderate-to-good sensitivity and specificity.  The authors concluded that based on current literature, it appears premature for routine application of MRI as an imaging modality to assess carotid plaque characteristics associated with plaque vulnerability.  They stated that although MRI still holds promise, clinical application for plaque characterization would require consensus regarding MRI settings and confirmation by histology.  Pre-defined protocols for histology and MR imaging need to be established.

Saam et al (2013) performed a systematic review and meta-analysis to determine precise estimates of the predictive value of carotid IPH as determined by MRI for cerebrovascular events.  These investigator searched PubMed, EMBASE, and the Cochrane Library through September 2012 for studies that followed more than 35 individuals after baseline MRI.  Independent observers abstracted information on populations, MR techniques, outcomes, and study quality.  Risk estimates of the presence of IPH for cerebrovascular events were derived in random effects regression analysis, and causes of heterogeneity were determined in meta-regression analysis.  These researchers identified 8 eligible studies including 689 participants who underwent carotid MRI.  The prevalence of IPH at baseline was high (49.0 %).  Over a median follow-up of 19.6 months, a total of 108 cerebrovascular events occurred (15.7 % event rate).  The presence of IPH was associated with an approximately 6-fold higher risk for events (HR: 5.69; 95 % CI: 2.98 to 10.87).  The annualized event rate in subjects with detectable IPH was 17.71 % compared with 2.43 % in patients without IPH.  Meta-regression analysis showed symptomatic subjects had higher risks as compared with asymptomatic subjects (HR: 11.71, 95 % CI: 5.17 to 26.48 versus HR: 3.50, 95 % CI: 2.59 to 4.73, p = 0.0065).  Also, differences were observed for sex and sample size (all p < 0.01), with moderate visual publication bias due to missing smaller sample-size studies (p = 0.18).  The authors concluded that presence of IPH on MRI strongly predicts cerebrovascular events.  Moreover, they stated that homogenization of future studies is needed to allow for sufficient assessment of level of evidence for intervention trials.

Graft Monitoring Following Heart Transplantation:

International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients (Costanzo, et al., 2010) state that the routine clinical use of MRI for acute allograft rejection monitoring is not recommended. Furthermore, an UpToDate review on “Clinical utility of cardiovascular magnetic resonance imaging” (Fuisz and Pohost, 2015) does not mention cardiac rejection as a potential indication of CMR.

Usman et al (2012) noted that acute rejection is a major factor impacting survival in the first 12 months after cardiac transplantation.  Transplant monitoring requires invasive techniques.  Cardiac magnetic resonance (CMR) has been used in monitoring heart transplants.  Prolonged T2 relaxation has been related to transplant edema and possibly rejection.  These researchers hypothesized that prolonged T2 reflects transplant rejection and that quantitative T2 mapping will concur with the pathological and clinical findings of acute rejection.  In a pilot study, patients were recruited within the 1st year after transplantation.  Biopsies were graded according to the International Society for Heart Lung Transplant system for cellular rejection with immunohistochemistry for humoral rejection.  Rejection was also considered if patients presented with signs and symptoms of hemodynamic compromise without biopsy evidence of rejection who subsequently improved with treatment.  Patients underwent a novel single-shot T2-prepared steady-state free precession 4-chamber and 3 short axis sequences and regions of interest were drawn overlying T2 maps by 2 independent blinded reviewers.  A total of 74 (68 analyzable) CMRs T2 maps in 53 patients were performed.  There were 4 cellular, 2 humoral, and 2 hemodynamic rejection cases.  The average T2 relaxation time for grade 0R (n = 46) and grade 1R (n = 17) was 52.5 ± 2.2 and 53.1 ± 3.3 ms (mean ± SD), respectively.  The average T2 relaxation for grade 2R (n = 3) was 59.6 ± 3.1 ms and 3R (n = 1) was 60.3 ms (all p value < 0.05 compared with controls).  The T2 average in humoral rejection cases (n = 2) was 59.2 ± 3.3 ms and the hemodynamic rejection (n = 2) was 61.1 ± 1.8 ms (p < 0.05 versus controls).  The average T2 relaxation time for all-cause rejection versus no rejection is 60.1 ± 2.1 versus 52.8 ± 2.7 ms (p < 0.05).  All rejection cases were rescanned 2.5 months after treatment and demonstrated T2 normalization with average of 51.4 ± 1.6 ms.  No difference was found in ventricular function between non-rejection and rejection patients, except in ventricular mass 107.8 ± 10.3 versus 127.5 ± 10.4 g (p < 0.05).  The authors concluded that quantitative T2 mapping offered a novel non-invasive tool for transplant monitoring, and these initial findings suggested potential use in characterizing rejections.  Given the limited numbers, a larger multi-institution study may help elucidate the benefits of T2 mapping as an adjunctive tool in routine monitoring of cardiac transplants.

Urbanowicz et al (2014) stated that diagnosis of rejection is a major objective in the management of heart transplant recipients.  It has been reported that 1/3 of protocol biopsies in asymptomatic, biochemically stable organ transplant recipients in the first 6 months show unsuspected subclinical graft rejection.  These researchers presented the case of a 43-year old man suffering from dilated cardiomyopathy who underwent orthotropic heart transplantation.  The patient was admitted for a protocol endomyocardial biopsy and MRI on the 4th post-operative month as a protocol procedure.  The examination revealed clinical status NYHA I with no signs of fatigue, diminution of exercise tolerance, or shortness of breath.  His body temperature was not raised.  He was referred for endomyocardial biopsy and cardiovascular magnetic resonance (CMR) imaging, which showed good left and right ventricle function and contractility.  T2 imaging revealed increased signal in the area of the right ventricular free wall, seen both in 4-chamber and short axis views.  The patient underwent an endomyocardial biopsy, which demonstrated diffuse infiltrate with multifocal miocyte damage and cellular edema recognized as acute rejection (3a ISHLT grade).  Consequently, the patient was treated with parenteral methylprednisolone administration.  The CMR study performed after 1 week of therapy showed that the signal intensity of the edematous areas was significantly decreased.  Repetitive endomyocardial biopsy revealed no signs of rejection.  The authors concluded that CMR can be helpful in graft monitoring following heart transplantation.  It gives a whole-heart perspective that can be competitive with and/or complementary to endomyocardial biopsy.

Diagnosis and Disease Monitoring of Cardiac Involvement in Systemic Amyloidosis:

American College of Cardiology appropriate use criteria for cardiac MRI (2006) rated evaluation of specific cardiomyopathies (infiltrative [amyloid, sarcoid], HCM, or due to cardiotoxic therapies) as an appropriate indication for cardiac MRI.

Barison et al (2015) noted that cardiac involvement in systemic amyloidosis is caused by the extracellular deposition of misfolded proteins, mainly immunoglobulin light chains (AL) or transthyretin (ATTR), and may be detected by CMR.  These researchers measured myocardial extra-cellular volume (ECV) in amyloid patients with a novel T1 mapping CMR technique and determined the correlation between ECV and disease severity.  A total of 36 patients with biopsy-proven systemic amyloidosis (mean age of 70 ± 9 years, 31 men, 30 with AL and 6 with ATTR amyloidosis) and 7 patients with possible amyloidosis (mean age of 64 ± 10 years, 6 men) underwent comprehensive clinical and CMR assessment, with ECV estimation from pre- and post-contrast T1 mapping; 30 healthy subjects (mean age of 39 ± 17 years, 21 men) served as the control group.  Amyloid patients presented with LV concentric hypertrophy with impaired bi-ventricular systolic function.  Cardiac ECV was higher in amyloid patients (definite amyloidosis, 0.43 ± 0.12; possible amyloidosis, 0.34 ± 0.11) than in control subjects (0.26 ± 0.04, p < 0.05); even in amyloid patients without late gadolinium enhancement (0.35 ± 0.10), ECV was significantly higher than in the control group (p < 0.01).  A cut-off value of myocardial ECV greater than 0.316, corresponding to the 95th percentile in normal subjects, showed a sensitivity of 79 % and specificity of 97 % for discriminating amyloid patients from control subjects (area under the curve of 0.884).  Myocardial ECV was significantly correlated with LVEF (R(2)  = 0.16), LV mean wall thickness (R(2)  = 0.41), LV diastolic function (R(2)  = 0.21), right ventricular ejection fraction (R(2)  = 0.13), N-terminal fragment of the pro-brain natriuretic peptides (R(2)  = 0.23) and cardiac troponin (R(2)  = 0.33).  The authors concluded that myocardial ECV was increased in amyloid patients and correlated with disease severity.  Thus, measurement of myocardial ECV represents a potential non-invasive index of amyloid burden for use in early diagnosis and disease monitoring.

Detection of Subclinical Cardiac Involvement in Kearns-Sayre Syndrome:

Kabunga et al (2015) stated that Kearns-Sayre syndrome (KSS) is a mitochondrial disorder characterized by onset before the age of 20 years, progressive external ophthalmoplegia, and pigmentary retinopathy, accompanied by cardiac conduction defects, elevated cerebrospinal fluid protein or cerebellar ataxia; 50 % of patients with KSS develop cardiac complications.  The most common cardiac manifestation is conduction disease that may progress to complete atrio-ventricular block or bradycardia-related polymorphic ventricular tachycardia (PMVT).  The management of cardiac electrical disease associated with KSS and mitochondrial cytopathy was systematically reviewed including the case of a 23-year old female patient with KSS who developed a constellation of cardiac arrhythmias including rapidly progressive conduction system disease and monomorphic ventricular tachycardia with myocardial scarring.  The emerging role of cardiac MRI (CMR) in detecting subclinical cardiac involvement was also highlighted.

An UpToDate review on “Mitochondrial myopathies: Clinical features and diagnosis” (Genge and Massie, 2105) states that “Kearns-Sayre syndrome (KSS) refers to the combination of CPEO [chronic progressive external ophthalmoplegia] with pigmentary retinopathy and onset before age 20.  Other abnormalities have been described, including short stature, cerebellar ataxia, raised CSF protein (> 100 mg/dL), cardiac conduction defects or cognitive deficits/mental retardation.  KSS is usually more aggressive than isolated CPEO, progressing to complete ophthalmoparesis, and often to death by the fourth decade due to the associated deficits.  Patients with either disorder can develop a proximal myopathy, which usually does not limit daily functioning, particularly for patients with CPEO”.  This review does not mention cardiac MRI as a management tool.

CPT Codes / HCPCS Codes / ICD-10 Codes
Information in the [brackets] below has been added for clarification purposes.   Codes requiring a 7th character are represented by "+":
ICD-10 codes will become effective as of October 1, 2015:
CPT codes covered if selection criteria are met:
75557 Cardiac magnetic resonance imaging for morphology and function without contrast material
75559     with stress imaging
75561 Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences
75563     with stress imaging
75565 Cardiac magnetic resonance imaging for velocity flow mapping
Other CPT codes related to the CPB:
71250 - 71270 Computed tomography, thorax
71550 - 71552 Magnetic resonance (e.g., proton) imaging, chest (e.g., for evaluation of hilar and mediastinal lymphadenopathy)
76604 Ultrasound, chest (includes mediastinum), real time with image documentation
77058 - 77059 Magnetic resonance imaging, breast, without and/or with contrast material(s)
78414 - 78499 Nuclear medicine, cardiovascular system imaging
HCPCS codes covered if selection criteria are met:
A9576 Injection, gadoteridol, (ProHance multipack), per ml
A9577 Injection, gadobenate dimeglumine (MultiHance), per ml
A9578 Injection, gadobenate dimeglumine (MultiHance multipack), per ml
A9579 Injection, gadolinium based magnetic resonance contrast agent, not otherwise specified, per ml
Other HCPCS codes related to the CPB:
J0151 Injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use A9270)
ICD-10 codes covered if selection criteria are met (not all-inclusive):
A18.89 Tuberculosis of other sites [myocardium]
A36.81 Diphtheritic cardiomyopathy
A39.52 Meningococcal myocarditis
A52.00 - A52.09 Cardiovascular and cerebrovascular syphilis
B33.22 Viral myocarditis
B58.81 Toxoplasma myocarditis
C34.00 - C38.8 Malignant neoplasm of bronchus and lung, thymus, heart, mediastium and pleura
C45.0
C45.2 		Mesothelioma of pleura and pericardium
C47.3
C49.3		 Malignant neoplasm of peripheral nerves of thorax and connective and soft tissue of thorax
C78.00 - C78.2 Secondary malignant neoplasm of lung, mediastinum and pleura
D14.30 - D14.32 Benign neoplasm of bronchus and lung
D15.0
D15.1
D15.2		 Benign neoplasm of thymus, heart and mediastinum
D17.4 Benign lipomatous neoplasm of intrathoracic organs
D19.0 Benign neoplasm of mesothelial tissue of pleura
D21.3 Benign neoplasm of connective and other soft tissue of thorax
D38.1 - D38.4 Neoplasm of uncertain behavior of trachea, bronchus, lung, pleura, mediastinum and thymus
D86.0 - D86.9 Sarcoidosis
E85.8 Other amyloidosis [nutritional and metabolic cardiomyopathy]
E85.9 Amyloidosis, unspecified [nutritional and metabolic cardiomyopathy]
I00 - I09.9 Acute rheumatic fever and chronic rheumatic heart diseases
I11.9 Hypertensive heart disease without heart failure
I20.0 Unstable angina
I21.01 - I22.9 Acute and subsequent ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction
I24.0 - I24.9 Other acute ischemic heart diseases
I25.110
I25.700
I25.710
I25.720
I25.730
I25.750
I25.760
I25.790		 Atherosclerosis of coronary artery with unstable angina pectoris
I26.01 - I26.99 Pulmonary embolism
I28.0 - I28.8 Other diseases of pulmonary vessels
I30.0 - I41 Other forms of heart disease
I42.0 - I43 Cardiomyopathies
I48.0 - I48.2, I48.91 Atrial fibrillation
I51.4 Myocarditis, unspecified
I67.0 Dissection of cerebral arteries, nonruptured
I70.201 - I70.799
I70.92		 Atherosclerosis
I71.00 - I71.9 Aortic aneurysm and dissection
I73.00 - I73.01
I73.1
I73.89 - I73.9		 Other peripheral vascular diseases
I74.01 - I74.19 Embolism and thrombosis of abdominal aorta and unspecified parts of aorta
I77.71 - I77.79 Other arterial dissection
I79.0 - I79.8 Disorders of arteries, arterioles and capillaries in diseases classified elsewhere
I81 Portal vein thrombosis
I82.0 Budd-Chiari syndrome
I82.220 - I82.221 Embolism and thrombosis of inferior vena cava
J86.9 Pyothorax without fistula
J90 Pleural effusion, not elsewhere classified
J91.0 Malignant pleural effusion
J92.0 - J92.9
J94.0 - J94.9		 Pleural plaque and other pleural conditions
K75.1 Phlebitis of portal vein
Q20.0 - Q28.9 Congenital malformations of the circulatory system
Q87.40 - Q87.43 Marfan's syndrome
R09.1 Pleurisy
R22.2 Localized swelling, mass and lump, trunk
R93.1
R93.8		 Abnormal findings on diagnostic imaging of heart and coronary circulation and other specified body structures
R94.31 Abnormal electrocardiogram [ECG] [EKG]
T82.817+ - T82.818+ Embolism of cardiac and vascular prosthetic devices, implants and grafts
Z98.61 Coronary angioplasty status
ICD-10 codes not covered for indications listed in the CPB:
T86.20 - T86.23 Complications of heart transplant
Z13.6 Encounter for screening for cardiovascular disorders [routine without signs or symptoms of disease]
Z94.1 Heart transplant status


The above policy is based on the following references:
    1. Steiner RE. Present and future clinical position of magnetic resonance imaging. Magn Reson Med. 1986;3(4)::473-490.
    2. Pohost GM, Ratner AV. Nuclear magnetic resonance - Potential applications in clinical cardiology. JAMA. 1984;251(10):1304-1309.
    3. No authors listed. Magnetic resonance imaging. Prologue. Council on Scientific Affairs. JAMA. 1987;258(22):3283-3285.
    4. American College of Radiology (ACR). Standard for the Performance of Magnetic Resonance Imaging. Reston, VA: ACR; 2000. Available at: http://www.acr.org/cgi-bin/fr?tmpl:standards00,pdf:pdf/cardiovascular_mri.pdf. Accessed January 25, 2001.
    5. van Voorthuisen AE. Evaluation of MRI today. Diagn Imaging Clin Med. 1986;55(1-2):5-8.
    6. Edelman RR, Warach S. Magnetic resonance imaging (2). N Engl J Med. 1993;328(11):785-791.
    7. Nagel E, Fleck E. Functional MRI in ischemic heart disease based on detection of contraction abnormalities. J Magn Reson Imaging. 1999;10(3):411-417.
    8. Nagel E, Bornstedt A, Hug J, et al. Noninvasive determination of coronary blood flow velocity with magnetic resonance imaging: Comparison of breath-hold and navigator techniques with intravascular ultrasound. Magn Reson Med. 1999;41(3):544-549.
    9. Nagel E, Lehmkuhl HB, Bocksch W, et al. Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: Comparison with dobutamine stress echocardiography. Circulation. 1999;99(6):763-770.
    10. American Heart Association (AHA). Medical /Scientific Statement. Practice Guidelines for the Use of Imaging in Transient Ischemic Attacks and Acute Stroke. Dallas, TX: AHA; 1994. Available at: http://www.americanheart.org/Scientific/statements/1994/
      069401.html. Accessed January 25, 2001.
    11. Braunwald E. Heart Disease: A Textbook of Cardiovascular Medicine. 5th ed. Philadelphia, PA: W. B. Saunders Company; 1997:317-335.
    12. Tapson VF, Carroll BA, Davidson BL, et al. The diagnostic approach to acute venous thromboembolism. Clinical practice guideline. American Thoracic Society. Am J Respir Crit Care Med. 1999;160(3):1043-1066.
    13. Morey SS. American Heart Association issues guidelines on imaging in transient ischemic attacks and stroke. Am Fam Physician. 1998;57(7):1682, 1685-1686.
    14. Culebras A, Kase CS, Masdeu JC, et al. Practice guidelines for the use of imaging in transient ischemic attacks and acute stroke. A report of the Stroke Council, American Heart Association. Stroke. 1997;28(7):1480-1497.
    15. No authors listed. Guidelines for the management of transient ischemic attacks. From the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks of the Stroke Council of the American Heart Association. Stroke. 1994;25(6):1320-1335.
    16. Link KM, Martin EM, Loehr SP. Cardica MRI. In: Textbook of Diagnostic Imaging. 2nd ed. CE Putnam, CE Ravin eds. Philadelphia, PA: WB Saunders Company; 1994;2:1728-1738.
    17. Baron MB. Magnetic Resonance Imaging of the Heart. In: Essentials of Radiologic Imaging. 6th ed. JH Juhl, AB Crummy, eds. Philadelphia, PA: JB Lippincott Company; 1993:1139-1148.
    18. Zerhouni EA. Magnetic Resonance Imaging of Acquired Heart Disease. In: Computed Tomography and Magnetic Resonance Imaging of the Whole Body. JR Haaga, DJ Sartoris, DF Lanzieri, et al, eds. St. Louis, MO: Mosby; 1994;1:788-818.
    19. Bonow RO, Carabello B, de Leon AC, et al. ACC/AHA Guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Heart Valve Dis. 1998;7(6):672-707.
    20. No authors listed. The clinical role of magnetic resonance in cardiovascular disease. Task Force of the European Society of Cardiology, in collaboration with the Association of European Paediatric Cardiologists. Eur Heart J. 1998;19(1):19-39.
    21. Kramer CM. Magnetic resonance imaging to identify the high-risk plaque. Am J Cardiol. 2002;90(10C):15L-17L.
    22. Earls JP, Ho VB, Foo TK, et al. Cardiac MRI: Recent progress and continued challenges. J Magn Reson Imaging. 2002;16(2):111-127.
    23. Fyfe DA, Parks WJ. Noninvasive diagnostics in congenital heart disease: Echocardiography and magnetic resonance imaging. Crit Care Nurs Q. 2002;25(3):26-36.
    24. Ontario Ministry of Health and Long-Term Care, Medical Advisory Secretariat. Functional cardiac magnetic resonance imaging in the assessment of myocardial viability and perfusion. Health Technology Scientific Literature Review. Toronto, ON: Ontario Ministry of Health and Long-Term Care; November 2003. Available at: http://www.health.gov.on.ca/english/providers/program/mas/reviews/
      review_cardio_mri_1103.html. Accessed August 12, 2005.
    25. Shan K, Constantine G, Sivananthan M, Flamm SD. Role of cardiac magnetic resonance imaging in the assessment of myocardial viability. Circulation. 2004;109(11):1328-1334.
    26. Aviram G, Fishman JE. Magnetic resonance imaging of the heart and great vessels. Can Assoc Radiol J. 2004;55(2):96-101.
    27. Lima JA, Desai MY. Cardiovascular magnetic resonance imaging: Current and emerging applications. J Am Coll Cardiol. 2004;44(6):1164-1171.
    28. Ray T, Biederman RW, Doyle M, Mankad S. Magnetic resonance imaging in the assessment of coronary artery disease. Curr Atheroscler Rep. 2005;7(2):108-114.
    29. Foerster V, Murtagh J, Lentle BC, et al.  CT and MRI for selected clinical disorders: A systematic review of clinical systematic reviews. Technology Report Issue 59. Ottawa, ON: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2005.
    30. Hendel RC, Patel MR, Kramer CM, et al; American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group; American College of Radiology; Society of Cardiovascular Computed Tomography; Society for Cardiovascular Magnetic Resonance; American Society of Nuclear Cardiology; North American Society for Cardiac Imaging; Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. J Am Coll Cardiol. 2006;48(7):1475-1497.
    31. Beanlands RS, Chow BJ, Dick A, et al; Canadian Cardiovascular Society; Canadian Association of Radiologists; Canadian Association of Nuclear Medicine; Canadian Nuclear Cardiology Society; Canadian Society of Cardiac Magnetic Resonance. CCS/CAR/CANM/CNCS/CanSCMR joint position statement on advanced noninvasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multidetector computed tomographic angiography in the diagnosis and evaluation of ischemic heart disease -- executive summary. Can J Cardiol. 2007;23(2):107-119.
    32. Kellenberger CJ, Yoo SJ, Buchel ER. Cardiovascular MR imaging in neonates and infants with congenital heart disease. Radiographics. 2007;27(1):5-18.
    33. Schaar JA, Mastik F, Regar E, et al. Current diagnostic modalities for vulnerable plaque detection. Curr Pharm Des. 2007;13(10):995-1001.
    34. Sharples L, Hughes V, Crean A, et al. Cost-effectiveness of functional cardiac testing in the diagnosis and management of coronary artery disease: A randomised controlled trial. The CECaT trial. Health Technol Assess. 2007;11(49):1-136.
    35. García-García HM, Gonzalo N, Granada JF, et al. Diagnosis and treatment of coronary vulnerable plaques. Expert Rev Cardiovasc Ther. 2008;6(2):209-222.
    36. Hauser TH, Manning WJ. The promise of whole-heart coronary MRI. Curr Cardiol Rep. 2008;10(1):46-50.
    37. Lau J, Kent D, Tatsioni A, et al. Vulnerable plaques. A brief review of the concept and proposed approaches to diagnosis and treatment. Prepared by theTufts-New England Medical Center AHRQ Evidence-based Practice Center. Contract No. 290-02-0022, Task Order #1. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ); January 22, 2004. Available at: http://www.ahrq.gov/clinic/ta/placque/placque.pdf. Accessed July 31, 2008.
    38. Breuckmann F, Nassenstein K, Bruder O, et al. Cardiac magnetic resonance imaging in the diagnosis of acute coronary syndrome. Basics and clinical value. Herz. 2008;33(2):129-135.
    39. Lockie T, Nagel E, Redwood S, Plein S. Use of cardiovascular magnetic resonance imaging in acute coronary syndromes. Circulation. 2009;119(12):1671-1681.
    40. Chalela JA. Evaluating the carotid plaque: Going beyond stenosis. Cerebrovasc Dis. 2009;27 Suppl 1:19-24.
    41. Lerakis S, McLean DS, Anadiotis AV, et al. Prognostic value of adenosine stress cardiovascular magnetic resonance in patients with low-risk chest pain. J Cardiovasc Magn Reson. 2009;11(1):37.
    42. Ishida M, Kato S, Sakuma H. Cardiac MRI in ischemic heart disease. Circ J. 2009;73(9):1577-1588.
    43. Chen S, Cunningham J. Magnetic resonance imaging for patients with valvular heart disease: A review of clinical-effectiveness. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health (CADTH); 2009.
    44. Murphy G, Argaez C. Cardiac Magnetic Resonance Imaging (MRI) for patients with coronary artery disease: A review of diagnostic accuracy. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health (CADTH); 2009.
    45. Schuetz GM, Zacharopoulou NM, Schlattmann P, Dewey M. Meta-analysis: Noninvasive coronary angiography using computed tomography versus magnetic resonance imaging. Ann Intern Med. 2010;152(3):167-177.
    46. Hundley WG, Bluemke DA, Finn JP, et al. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010;121(22):2462-2508.
    47. Hoffman U, Venkatesh V, White RD, et al; Expert Panel on Cardiac Imaging. ACR Appropriateness Criteria acute nonspecific chest pain - low probability of coronary artery disease [online publication]. Reston, BA: American College of Radiology (ACR); 2011.
    48. Qian D, Bottomley PA. High-resolution intravascular magnetic resonance quantification of atherosclerotic plaque at 3T. J Cardiovasc Magn Reson. 2012;14:20.
    49. Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2012;14:13.
    50. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012;5(4):370-377.
    51. Gulati A, Jabbour A, Ismail TF, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309(9):896-908.
    52. Ammash NM, Connolly HM. Ventricular septal defect in adults. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed April 2013.
    53. Ramaswamy P. Ventricular septal defects. New York, NY: MedScape, LLC.; April 17, 2013. Available at: http://emedicine.medscape.com/article/892980-overview.
    54. Bauner KU, Wintersperger B. MRI in cardiac sarcoidosis and amyloidosis. Radiologe. 2013;53(1):54-60.
    55. Mckenna MJ. Cardiac sarcoidosis. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed April 2013. 
    56. Scott PA, Rosengarten JA, Curzen NP, Morgan JM. Late gadolinium enhancement cardiac magnetic resonance imaging for the prediction of ventricular tachyarrhythmic events: A meta-analysis. Eur J Heart Fail. 2013;15(9):1019-1027.
    57. den Hartog AG, Bovens SM, Koning W, et al. Current status of clinical magnetic resonance imaging for plaque characterisation in patients with carotid artery stenosis. Eur J Vasc Endovasc Surg. 2013;45(1):7-21.
    58. Saam T, Hetterich H, Hoffmann V, et al. Meta-analysis and systematic review of the predictive value of carotid plaque hemorrhage on cerebrovascular events by magnetic resonance imaging. J Am Coll Cardiol. 2013;62(12):1081-1091.
    59. Usman AA, Taimen K, Wasielewski M, et al. Cardiac magnetic resonance T2 mapping in the monitoring and follow-up of acute cardiac transplant rejection: A pilot study. Circ Cardiovasc Imaging. 2012;5(6):782-790.
    60. Snorek M, Bulava A. MRI compatible cardiac pacemakers and implantable cardioverter defibrillators. Vnitr Lek. 2014;60(2):123-127.
    61. Urbanowicz T, Kociemba A, Pyda M, et al. Cardiovascular magnetic resonance imaging in asymptomatic acute heart rejection: A case report. Ann Transplant. 2014;19:447-451.
    62. Fuisz AR, Pohost GM. Clinical utility of cardiovascular magnetic resonance imaging. UpToDate Inc., Waltham, MA. Last reviewed March 2015.
    63. Costanzo MR, Dipchand A, Starling R, et al.; International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29(8):914-956.
    64. Barison A, Aquaro GD, Pugliese NR, et al. Measurement of myocardial amyloid deposition in systemic amyloidosis: Insights from cardiovascular magnetic resonance imaging. J Intern Med. 2015;277(5):605-614.
    65. Kabunga P, Lau AK, Phan K, et al. Systematic review of cardiac electrical disease in Kearns-Sayre syndrome and mitochondrial cytopathy. Int J Cardiol. 2015;181:303-310.
    66. Genge A, Massie R. Mitochondrial myopathies: Clinical features and diagnosis. UpToDate Inc., Waltham, MA. Last reviewed March 2015.
    67. Nordbeck P, Ertl G, Ritter O. Magnetic resonance imaging safety in pacemaker and implantable cardioverter defibrillator patients: How far have we come? Eur Heart J. 2015;36(24):1505-1511.
    68. Kawaji K, Foppa M, Roujol S, et al. Whole heart coronary imaging with flexible acquisition window and trigger delay. PLoS One. 2015;10(2):e0112020.
    69. Hamshere S, Jones DA, Pellaton C, et al. Cardiovascular magnetic resonance imaging of myocardial oedema following acute myocardial infarction: Is whole heart coverage necessary? J Cardiovasc Magn Reson. 2016;18(1):7.


Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.
 
Copyright © 2001-[current-year] Aetna Inc.
You are now leaving the Aetna website.

Links to various non-Aetna sites are provided for your convenience only. Aetna Inc. and its subsidiary companies are not responsible or liable for the content, accuracy, or privacy practices of linked sites, or for products or services described on these sites.

Continue >